Co-prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine-Associated Hypotension: A Retrospective Cohort Study.

In conclusion, CYP1A2 inhibition increases the risk of hypotensive episodes associated with the use of tizanidine in routine clinical practice. This article is protected by copyright. All rights reserved.
PMID: 30223305 [PubMed - as supplied by publisher]

Source: Clinical Pharmacology and Therapeutics - September 17, 2018 Category: Drugs & Pharmacology Authors: Chaugai S, Dickson AL, Shuey MM, Feng Q, Barker KA, Wei WQ, Luther JM, Stein CM, Chung CP Tags: Clin Pharmacol Ther Source Type: research